ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report)'s stock had its "overweight" rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $30.00 target price on the stock. Cantor Fitzgerald's target price indicates a potential upside of 117.86% from the company's current price.
Several other equities analysts have also issued reports on SPRY. William Blair raised ARS Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Leerink Partners increased their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an "outperform" rating in a research note on Friday, September 20th. Finally, Raymond James upgraded shares of ARS Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and upped their target price for the stock from $18.00 to $22.00 in a research report on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, ARS Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $24.00.
View Our Latest Report on ARS Pharmaceuticals
NASDAQ:SPRY traded up $0.11 during trading hours on Tuesday, reaching $13.77. The stock had a trading volume of 179,825 shares, compared to its average volume of 755,405. ARS Pharmaceuticals has a 12-month low of $3.35 and a 12-month high of $16.50. The stock has a 50 day simple moving average of $12.75 and a 200 day simple moving average of $10.48. The stock has a market cap of $1.33 billion, a P/E ratio of -26.56 and a beta of 0.91.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $2.00 million. On average, equities analysts expect that ARS Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 12,500 shares of the company's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $16.00, for a total value of $200,000.00. Following the completion of the transaction, the chief financial officer now owns 13,199 shares in the company, valued at $211,184. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other ARS Pharmaceuticals news, CEO Richard E. Lowenthal sold 100,000 shares of the company's stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $11.40, for a total value of $1,140,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,547,447 shares of the company's stock, valued at approximately $17,640,895.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kathleen D. Scott sold 12,500 shares of the firm's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $16.00, for a total transaction of $200,000.00. Following the transaction, the chief financial officer now directly owns 13,199 shares in the company, valued at approximately $211,184. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 943,395 shares of company stock valued at $12,688,032. Corporate insiders own 40.10% of the company's stock.
Several institutional investors and hedge funds have recently made changes to their positions in SPRY. J.W. Cole Advisors Inc. increased its stake in shares of ARS Pharmaceuticals by 10.8% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company's stock valued at $131,000 after acquiring an additional 1,500 shares during the last quarter. Levin Capital Strategies L.P. increased its position in shares of ARS Pharmaceuticals by 5.7% in the first quarter. Levin Capital Strategies L.P. now owns 55,250 shares of the company's stock worth $565,000 after purchasing an additional 3,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock worth $63,000 after purchasing an additional 4,472 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of ARS Pharmaceuticals during the first quarter valued at about $60,000. Finally, FAS Wealth Partners Inc. boosted its stake in shares of ARS Pharmaceuticals by 11.9% during the second quarter. FAS Wealth Partners Inc. now owns 67,656 shares of the company's stock valued at $576,000 after purchasing an additional 7,186 shares in the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.